TBI Therapeutics

TBI Therapeutics is a biotechnology company dedicated to developing the first effective pharmacological treatments for traumatic brain injury (TBI) and concussions. The company's lead research focuses on small molecule therapies designed to mitigate the secondary injury cascade that follows initial head trauma, specifically targeting neurotoxicity and inflammation. By addressing the underlying biochemical pathways of brain damage, TBI Therapeutics aims to improve long-term cognitive outcomes and prevent the development of chronic traumatic encephalopathy (CTE). The company operates primarily in the pre-clinical stage, leveraging partnerships with academic institutions and government agencies to advance its neuroprotective candidates.